# Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

> **NCT00625664** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 337 (actual)

## Conditions studied

- Urinary Bladder Neoplasms

## Interventions

- **DRUG:** larotaxel (XRP9881)
- **DRUG:** gemcitabine
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT00625664
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2011-02
- **Final completion:** 2011-02
- **Target enrollment:** 337 (ACTUAL)
- **Last updated:** 2016-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00625664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00625664, "Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00625664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*